# Management of Cardiovascular Disease in Kidney Disease (MaCK) Study

Study · id `cardio:ct-nct03636152` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03636152](<https://clinicaltrials.gov/study/NCT03636152>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03636152

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: Coronary and vascular disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT03636152. Randomized; quadruple masking; primary purpose treatment. Start 2018-12-14 (actual); primary completion 2024-01-31 (actual). Results posted on 2026-08-20.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03636152, source copy `cardio:ctgov-nct03636152-2026-08-20`, retrieved 2026-10-26)
- Started: 2018-12-14 (actual) (ClinicalTrials.gov record NCT03636152, source copy `cardio:ctgov-nct03636152-2026-08-20`, retrieved 2026-10-26)
- Primary completion: 2024-01-31 (actual) (ClinicalTrials.gov record NCT03636152, source copy `cardio:ctgov-nct03636152-2026-08-20`, retrieved 2026-10-26)
- Completion: 2024-01-31 (actual) (ClinicalTrials.gov record NCT03636152, source copy `cardio:ctgov-nct03636152-2026-08-20`, retrieved 2026-10-26)
- Results first posted: 2026-08-20 (ClinicalTrials.gov record NCT03636152, source copy `cardio:ctgov-nct03636152-2026-08-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03636152, source copy `cardio:ctgov-nct03636152-2026-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03636152-2026-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Management of Cardiovascular Disease in Kidney Disease (MaCK) Study
- Acronym: MaCK
- Condition: Chronic Kidney Disease
- Condition: Cardiovascular Disease
- Condition: Inflammation
- Condition: Atherosclerosis
- Condition: Aortic Stiffness
- Intervention (Procedure): MRI carotid
- Intervention (Procedure): APWV
- Intervention (Drug): Hydroxychloroquine
- Intervention (Drug): Matching Placebo
- Lead sponsor: VA Office of Research and Development
- Lead sponsor class: FED

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: VA Office of Research and Development (`cardio:org-va-office-of-research-and-development`)

## Provenance

Content hash: 3ba921b38c8f081fc84be17895438095ec63f6020fc40606490604cbd1b581e8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
